Epigenetic Regulation of Galectin-1 and Galectin-3 in Osteoporosis: A Pilot Study in Patients Undergoing Total Joint Arthroplasty.
Marina Russo, Gianluca Conza, Caterina Claudia Lepre, Gabriele Martin et al.
Kernaussage
Osteoporotic bone exhibits significantly reduced Gal-1 and increased Gal-3, miR-22, and miR-21, with serum showing reduced Gal-1 and miR-22 and increased miR-21, suggesting a co-dysregulation pattern of these biomarkers in osteoporosis.
Abstract
Background: Osteoporosis (OP) is a chronic disease characterized by decreased bone mass and altered microarchitecture, leading to bone fragility and fracture risk. To date, although carbohydrate-binding proteins Galectins 1 and 3 (Gal-1/Gal-3) have been implicated in bone metabolism, inflammation and aging, their levels and potential regulation by microRNAs (miRNAs) have not yet been investigated in OP. Methods: In this pilot study, 13 osteoporotic (OP) and 10 non-osteoporotic (NOP) patients, all undergoing hip or knee arthroplasty, were enrolled. Due to the unavailability of DXA measurements, OP classification was based on cortical bone ratio and distal femoral cortical index. Clinical parameters and blood samples were collected preoperatively, while bone biopsies were obtained intraoperatively. ELISA and qRT-PCR were used to quantify Gal-1, Gal-3, miR-22 and miR-21 in bones and sera. Correlations with clinical parameters were assessed. Results: Several OP biopsies exhibited a reduction in Gal-1 levels, whereas miR-22, Gal-3 and miR-21 were increased. Serum analysis revealed similar dysregulation patterns, with increased miR-21 and decreased Gal-1 and miR-22 levels in several OP patients. Conclusions: This pilot study suggests a putative association of Gal-1, Gal-3, and their previously reported related miRNAs with osteoporotic bone status, indicating their potential involvement in OP-related bone metabolism.
Kein medizinischer Rat. Die dargestellten Studien dienen der wissenschaftlichen Information und ersetzen keine ärztliche Beratung. Bei gesundheitlichen Fragen wende dich an eine approbierte Ärztin oder einen Arzt.
Quelle: PubMed Central / National Library of Medicine (NLM). Apollion steht in keiner Verbindung mit NLM und wird von NLM nicht empfohlen. Evidenzgrade bewerten die methodische Studienqualität — nicht die inhaltliche Richtigkeit.
Lizenz: CC BY — Inhalte werden ausschließlich aus Open-Access-Quellen mit kommerziell nutzbaren Lizenzen (CC0, CC BY, CC BY-SA) indexiert.